LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 424

Suchoptionen

  1. Buch ; Online ; E-Book: Gender and migraine

    Maassen Van Den Brink, Antoinette / MacGregor, E Anne

    (Headache)

    2019  

    Verfasserangabe Antoinette Maassen van den Brink, E. Anne MacGregor editors
    Serientitel Headache
    Schlagwörter Internal medicine ; Neurology ; Toxicology
    Thema/Rubrik (Code) 616
    Sprache Englisch
    Umfang 1 Online-Ressource (ix, 127 Seiten), Illustrationen
    Verlag Springer
    Erscheinungsort Cham
    Erscheinungsland Schweiz
    Dokumenttyp Buch ; Online ; E-Book
    Bemerkung Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT020030533
    ISBN 978-3-030-02988-3 ; 9783030029876 ; 3-030-02988-3 ; 3030029875
    DOI 10.1007/978-3-030-02988-3
    Datenquelle ZB MED Katalog Medizin, Gesundheit, Ernährung, Umwelt, Agrar

    Kategorien

  2. Artikel ; Online: Hormone replacement therapy (HRT) in perimenopausal women with migraine.

    MacGregor, E Anne / Briggs, Paula

    Post reproductive health

    2024  Band 30, Heft 1, Seite(n) 64–66

    Mesh-Begriff(e) Female ; Humans ; Perimenopause ; Hormone Replacement Therapy ; Estrogen Replacement Therapy ; Migraine Disorders/drug therapy
    Sprache Englisch
    Erscheinungsdatum 2024-02-22
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2753537-X
    ISSN 2053-3705 ; 2053-3691
    ISSN (online) 2053-3705
    ISSN 2053-3691
    DOI 10.1177/20533691241237110
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Differences Between Perimenstrual Migraine Attacks and Migraine Attacks at Other Times of the Cycle.

    MacGregor, E Anne

    Neurology

    2021  Band 97, Heft 17, Seite(n) e1753–e1756

    Mesh-Begriff(e) Adult ; Female ; Hormonal Contraception/adverse effects ; Humans ; Menstrual Cycle ; Middle Aged ; Migraine Disorders/etiology ; Migraine Disorders/physiopathology
    Sprache Englisch
    Erscheinungsdatum 2021-10-25
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/WNL.0000000000012741
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Menstrual and perimenopausal migraine: A narrative review.

    MacGregor, E Anne

    Maturitas

    2020  Band 142, Seite(n) 24–30

    Abstract: Migraine is affected by the changing hormone environment, with perimenopause associated with increased migraine, particularly menstrual migraine. Menstrual attacks are recognised to be more disabling and less responsive to treatment compared with non- ... ...

    Abstract Migraine is affected by the changing hormone environment, with perimenopause associated with increased migraine, particularly menstrual migraine. Menstrual attacks are recognised to be more disabling and less responsive to treatment compared with non-menstrual attacks. Perimenstrual estrogen 'withdrawal' is implicated in the pathophysiology of menstrual migraine, with increased prevalence of migraine in perimenopause associated with unpredictable estrogen fluctuations. Perimenopausal women often have contraceptive needs as well as menopause symptoms and it is important to understand the potential effects of exogenous hormones on migraine. Maintaining stable estrogen levels with exogenous hormones can benefit migraine but clinical trial data are limited. This short narrative review addresses the diagnosis and management of menstrual migraine in perimenopausal women, and discusses the management of menopause symptoms in peri- and postmenopausal women with migraine.
    Mesh-Begriff(e) Female ; Humans ; Menopause ; Menstruation ; Migraine Disorders/drug therapy ; Migraine Disorders/physiopathology
    Sprache Englisch
    Erscheinungsdatum 2020-07-10
    Erscheinungsland Ireland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 80460-5
    ISSN 1873-4111 ; 0378-5122
    ISSN (online) 1873-4111
    ISSN 0378-5122
    DOI 10.1016/j.maturitas.2020.07.005
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Universal ophthalmia neonatorum prophylaxis in Ontario: a cost-effectiveness analysis.

    Rowlands Snyder, Ellen C / McGregor, Elspeth / Coyle, Doug

    CMAJ open

    2023  Band 11, Heft 1, Seite(n) E33–E39

    Abstract: Background: Although prophylaxis for ophthalmia neonatorum at birth is required by law in Ontario, declining prevalence of disease and efficacy of prophylaxis have called this practice into question. The objective of this modelling study was to assess ... ...

    Abstract Background: Although prophylaxis for ophthalmia neonatorum at birth is required by law in Ontario, declining prevalence of disease and efficacy of prophylaxis have called this practice into question. The objective of this modelling study was to assess the cost-effectiveness of universal prophylaxis for ophthalmia neonatorum to inform decision-makers on the potential impact of a change in this policy.
    Methods: We compared the cost-effectiveness of prophylaxis for ophthalmia neonatorum with no prophylaxis through cost-utility analysis with a lifetime time horizon, considering a provincial government payer, for a hypothetical population of newborns in Ontario. We assessed both the mean incremental costs of prophylaxis and its mean incremental effectiveness using a hybrid (part decision tree, part Markov) model. We used a scenario analysis to evaluate alternative time horizons and discount rates. We conducted a threshold analysis to evaluate the impact of variations in the cost of prophylaxis and in the prevalence of sexually transmitted infections (gonorrhea and chlamydia).
    Results: In our model, prophylaxis for ophthalmia neonatorum did not meet a willingness-to-pay threshold of Can$50 000 per quality-adjusted life-year (QALY). Although prophylaxis was effective in reducing morbidity associated with ophthalmia neonatorum, the number needed to treat to prevent 1 case of ophthalmia neonatorum blindness was 500 000, with an associated cost of more than Can$4 000 000. When compared with no prophylaxis, prophylaxis had an incremental cost of Can$355 798 per long-term QALY gained (incremental cost-effectiveness ratio).
    Interpretation: We found that prophylaxis for ophthalmia neonatorum, although individually inexpensive, leads to very high costs on a population level. These findings contribute to the discussion on mandatory prophylaxis currently underway in several jurisdictions.
    Mesh-Begriff(e) Humans ; Infant, Newborn ; Ophthalmia Neonatorum/epidemiology ; Ophthalmia Neonatorum/prevention & control ; Ophthalmia Neonatorum/drug therapy ; Cost-Effectiveness Analysis ; Ontario/epidemiology ; Gonorrhea/epidemiology ; Gonorrhea/prevention & control ; Cost-Benefit Analysis
    Sprache Englisch
    Erscheinungsdatum 2023-01-17
    Erscheinungsland Canada
    Dokumenttyp Journal Article
    ZDB-ID 2701622-5
    ISSN 2291-0026 ; 2291-0026
    ISSN (online) 2291-0026
    ISSN 2291-0026
    DOI 10.9778/cmajo.20210226
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Migraine (Japanese Version).

    MacGregor, E Anne

    Annals of internal medicine

    2018  Band 166, Heft 7, Seite(n) JITC49–JITC64

    Sprache Englisch
    Erscheinungsdatum 2018-11-02
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/IsTranslatedFrom_AITC201704040_Japanese
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Buch ; Dissertation / Habilitation: Benchmarking Verwaltungen von Universitätskliniken

    Jung, Gregor Eric

    2008  

    Verfasserangabe vorgelegt von Gregor Erich Jung
    Thema/Rubrik (Code) 362.11068
    Sprache Deutsch
    Umfang 75 S., Ill., graph. Darst., Kt.
    Erscheinungsland Deutschland
    Dokumenttyp Buch ; Dissertation / Habilitation
    Dissertation / Habilitation Kiel, Univ., Diss., 2008
    HBZ-ID HT016149949
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Disentangling the Molecular Mechanisms of the Antidepressant Activity of Omega-3 Polyunsaturated Fatty Acid

    Hans O. Kalkman / Martin Hersberger / Suzanne Walitza / Gregor E. Berger

    International Journal of Molecular Sciences, Vol 22, Iss 4393, p

    A Comprehensive Review of the Literature

    2021  Band 4393

    Abstract: Major depressive disorders (MDDs) are often associated with a deficiency in long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFAs), as well as signs of low-grade inflammation. Epidemiological and dietary studies suggest that a high intake of fish, ... ...

    Abstract Major depressive disorders (MDDs) are often associated with a deficiency in long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFAs), as well as signs of low-grade inflammation. Epidemiological and dietary studies suggest that a high intake of fish, the major source of ω-3 PUFAs, is associated with lower rates of MDDs. Meta-analyses of randomized placebo-controlled ω-3 PUFAs intervention-trials suggest that primarily eicosapentaenoic acid (EPA), but not docosahexaenoic acid (DHA), is responsible for the proposed antidepressant effect. In this review, we dissect the current biological knowledge on EPA and DHA and their bioactive lipid metabolites to search for a pharmacological explanation of this, to date, unexplained clinical observation. Through enzymatic conversion by cyclooxygenase (COX), lipoxygenase (ALOX), and cytochrome P-450 monooxygenase (CYP), EPA and DHA are metabolized to major anti-inflammatory and pro-resolving lipid mediators. In addition, both ω-3 PUFAs are precursors for endocannabinoids, with known effects on immunomodulation, neuroinflammation, food intake and mood. Finally, both ω-3 PUFAs are crucial for the structure and organization of membranes and lipid rafts. While most biological effects are shared by these two ω-3 PUFAs, some distinct features could be identified: (1) The preferential CYP monooxygenase pathway for EPA and EPA derived eicosanoids; (2) The high CB2 receptor affinities of EPA-derived EPEA and its epoxy-metabolite 17,18-EEQ-EA, while the DHA-derived endocannabinoids lack such receptor affinities; (3) The competition of EPA but not DHA with arachidonic acid (AA) for particular glycerophospholipids. EPA and AA are preferentially incorporated into phosphatidylinositols, while DHA is mainly incorporated into phosphatidyl-ethanolamine, -serine and -choline. We propose that these distinct features may explain the superior antidepressant activity of EPA rich ω-3 PUFAs and that these are potential novel targets for future antidepressant drugs.
    Schlagwörter ω-3 polyunsaturated fatty acid ; EPA-paradox ; resolvin ; cytochrome P450 isoenzyme ; epoxide ; endocannabinoid ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Sprache Englisch
    Erscheinungsdatum 2021-04-01T00:00:00Z
    Verlag MDPI AG
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Migraine, menopause and hormone replacement therapy.

    MacGregor, E Anne

    Post reproductive health

    2017  Band 24, Heft 1, Seite(n) 11–18

    Abstract: Perimenopause marks a period of increased migraine prevalence in women and many women also report troublesome vasomotor symptoms. Migraine is affected by fluctuating estrogen levels with evidence to support estrogen 'withdrawal' as a trigger of menstrual ...

    Abstract Perimenopause marks a period of increased migraine prevalence in women and many women also report troublesome vasomotor symptoms. Migraine is affected by fluctuating estrogen levels with evidence to support estrogen 'withdrawal' as a trigger of menstrual attacks of migraine without aura, while high estrogen levels can trigger migraine aura. Maintaining a stable estrogen environment with estrogen replacement can benefit estrogen-withdrawal migraine particularly in women who would also benefit from relief of vasomotor symptoms. In contrast to contraceptive doses of ethinylestradiol, migraine aura does not contraindicate use of physiological doses of natural estrogen. In women with migraine with or without aura, using only the lowest doses of transdermal estrogen necessary to control vasomotor symptoms minimizes the risk of unwanted side effects. Cyclical progestogens can have an adverse effect on migraine so continuous progestogens, as provided by the levonorgestrel intrauterine system or in continuous combined transdermal preparation, are preferred. There are no data on the effect of micronized progesterone on migraine, either cyclical or continuous. Non-hormonal options for both conditions are limited but there is evidence of efficacy for escitalopram and venflaxine.
    Mesh-Begriff(e) Brain Ischemia/etiology ; Estrogens/adverse effects ; Estrogens/blood ; Estrogens/therapeutic use ; Estrogens, Conjugated (USP)/therapeutic use ; Female ; Hormone Replacement Therapy/adverse effects ; Hormone Replacement Therapy/methods ; Hot Flashes/drug therapy ; Humans ; Migraine Disorders/blood ; Migraine Disorders/diagnosis ; Migraine Disorders/prevention & control ; Perimenopause ; Progestins/therapeutic use ; Stroke/etiology ; Sweating
    Chemische Substanzen Estrogens ; Estrogens, Conjugated (USP) ; Progestins
    Sprache Englisch
    Erscheinungsdatum 2017-10-10
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2753537-X
    ISSN 2053-3705 ; 2053-3691
    ISSN (online) 2053-3705
    ISSN 2053-3691
    DOI 10.1177/2053369117731172
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Migraine.

    MacGregor, E Anne

    Annals of internal medicine

    2017  Band 166, Heft 7, Seite(n) ITC49–ITC64

    Abstract: This issue provides a clinical overview of migraine, focusing on risk, prevention, diagnosis, treatment, follow-up, and practice improvement. The content of In the Clinic is drawn from the clinical information and education resources of the American ... ...

    Abstract This issue provides a clinical overview of migraine, focusing on risk, prevention, diagnosis, treatment, follow-up, and practice improvement. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance of additional science writers and physician writers.
    Mesh-Begriff(e) Analgesics/therapeutic use ; Behavior Therapy ; Diagnosis, Differential ; Humans ; Migraine Disorders/diagnosis ; Migraine Disorders/etiology ; Migraine Disorders/prevention & control ; Migraine Disorders/therapy ; Patient Education as Topic ; Risk Factors
    Chemische Substanzen Analgesics
    Sprache Englisch
    Erscheinungsdatum 2017-04-04
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/AITC201704040
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang